Common cold
Drug research and approvals for common cold: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 12 studies of common cold are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 12
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 12 recruiting on ClinicalTrials.gov ↗- Effect of Immune X on Common Cold Incidence in Healthy AdultsNCT07787130 · Not applicable · Givaudan France Naturals · starts Oct 9, 2026
- Probiotic Trial for URTI Prevention in Healthy AdultsNCT07908797 · Not applicable · Harokopio University · starts Oct 1, 2026
- Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving…NCT07626437 · Phase 3 · Brainfarma Industria QuÃmica e Farmacêutica S/A · starts May 8, 2026
- Sex Differences in Cold-Induced Changes in Maximal Fat OxidationNCT07297823 · Not applicable · Colorado State University · starts Apr 15, 2026
- RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and RhinopharyngitisNCT07383493 · Not applicable · University Hospital, Clermont-Ferrand · starts Feb 25, 2026
- Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.NCT07314593 · Not applicable · Landspitali University Hospital · starts Dec 19, 2025
- Immune Defense Protein Impact On Respiratory Immune OutcomesNCT07431840 · Not applicable · Quantec Ltd · starts Dec 5, 2025
- Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From…NCT06580210 · Not reported · Laboratoires Gilbert · starts Oct 22, 2024
- A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common ColdNCT06697886 · Phase 3 · Tasly Pharmaceutical Group Co., Ltd · starts Nov 16, 2023
- Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in…NCT05494346 · Not applicable · Laboratoires Gilbert · starts Jun 23, 2023
Drug pipeline
18 approved, 10 in phase 3, 6 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Acetaminophen, Phenylephrine, Ibuprofen, Aspirin, Dextromethorphan, Pseudoephedrine, Menthol, Naphazoline, Oxymetazoline, Naproxen, Ephedrine, Ipratropium, Chlorpheniramine, Brompheniramine, Clemastine, Triprolidine, Diphenhydramine, Camphor
- Echinacea, unspecified
- Phase 3
- Acetylcysteine
- Phase 3 Glutathione precursor
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Azelastine
- Phase 3 Histamine H1 receptor antagonist
- Desloratadine
- Phase 3 Histamine H1 receptor antagonist
- Pheniramine
- Phase 3 Histamine H1 receptor antagonist
- Capsaicin
- Phase 3 Vanilloid receptor opener
- Caffeine
- Phase 3 Adenosine receptor antagonist
- Xylometazoline
- Phase 3 Adrenergic receptor alpha agonist
- Panthenol
- Phase 3
- Carbomer 910
- Phase 2
- 2-DEOXY-D-GLUCOSE
- Phase 2
- Cholecalciferol
- Phase 2 Vitamin D receptor agonist
- Guaifenesin
- Phase 2 Unknown
- Dextrose
- Phase 2
- Glucose oxidase
- Phase 2
- Glucagon
- Phase 1 Glucagon receptor agonist
How its trials ended
157 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 41 whose ending is known, 44% met their primary endpoint, 15% missed it and 41% stopped early.
- Completed, result not reported9259%
- Met its primary endpoint1811%
- Ongoing149%
- Stopped: other or unclear138%
- Status unknown106%
- Missed its primary endpoint64%
- Stopped: enrollment or feasibility32%
- Stopped: lack of efficacy11%
Trials authorized in Canada
Newest first; search them all in Canada trials| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jul 27, 2017 | Randomized, double-blind, placebo-controlled, study of the efficacy of phenylephrine hcl extended-release 30 mg and phenylephrine hcl immediate-release 12 mg…Phenylephrine | Johnson & Johnson Consumer | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA